Dr Prem Kumar Nair, Group Chief Executive Officer, IHH Healthcare, said, “Adding proton therapy to IHH’s comprehensive suite of cancer treatment in Singapore solidifies our standing as a Centre Of Excellence for oncology in Asia. Demand has already surpassed our expectations, and we are ramping up further to provide this cutting-edge treatment option to more patients across the region, as part of our purpose to touch lives and transform care.”
“Cancer patients are not alone in their fight against cancer. IHH Healthcare Singapore’s investment in proton therapy demonstrates our unwavering resolve to provide our patients with the best care,” said Dr Peter Chow, Chief Executive Officer, IHH Healthcare Singapore. “Up to half of all oncology patients require some form of radiation treatment but the side effects of treatment can be as debilitating as the cancer itself. Patients that are suited to undergo proton therapy will benefit from less side effects and damage to surrounding tissues due to the targeted nature of the proton beam.”
Proton therapy possesses unique properties that enable it to kill cancerous cells without causing as much damage to neighbouring tissue and organs. This means patients can better preserve function and enjoy higher long-term quality of life, which is especially critical and life-changing for younger patients.
The centre enhances MNH’s broad spectrum of oncology treatment modalities, including surgery, chemotherapy, and conventional radiotherapy, and is particularly beneficial for complex anatomical sites, sensitive tissues, and paediatric cases.
